Core Viewpoint - Hansai Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. successfully listed on the Hong Kong Stock Exchange, raising a total of HKD 586 million with an issue price of HKD 32 per share, enhancing its market capitalization to nearly HKD 4.4 billion [1] Company Overview - Established in 2014, the company focuses on developing innovative drugs for precise treatment of cancer and autoimmune diseases [1] - Currently, the company has a pipeline of 10 candidate drugs, with 3 in clinical stages and 7 in preclinical stages [1] Key Product Information - The core product, HX009, is a bispecific antibody fusion protein targeting both CD47 and PD-1, addressing indications such as melanoma and colorectal cancer [1] - HX009 is leading globally in clinical trial progress among similar products, having completed Phase I clinical trials in China and Australia, and is advancing multiple Phase II clinical trials in China [1] Market Impact - The successful listing on the main board of the Hong Kong Stock Exchange is expected to significantly enhance the company's industry influence, promote its brand globally, and facilitate more standardized and transparent corporate governance [1]
热烈祝贺翰思艾泰成功在港交所主板上市